spacer
home > pmps > summer 2002 > options in materials for liquid-filled capsules
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Options in Materials for Liquid-Filled Capsules

This article describes the current status of some potential substitutes for gelatine two-piece capsules, with particular reference to their suitability for liquid products. Animal gelatine presents a number of issues, including technical, regulatory, commercial and consumer acceptability aspects. The use of possible substitutes - 'fish gelatine', starch and hydroxypropyl methylcellulose (HPMC) - is discussed. Particular reference is made to progress in the suitability of HPMC capsules for commercial manufacture (including filling and sealing). The article will also include relevant comment on their current regulatory status.

Hard (or 'two-piece') capsules have been used in medicines for many years, and are also being used in increasing quantities in nutraceuticals. The commercial manufacturing process for the capsule shell itself was first established for gelatine in 1913. It led to the development of major automatic machines which form the basis of current shell manufacture worldwide.

The raw material gelatine, however, is derived from animal material and has presented a wide range of issues (technical, regulatory, commercial, limits to consumer selection according to religious or dietary needs) and there have been many investigations and commercial efforts to identify possible substitutes (1). In recent years, safety concerns about transmissible spongiform encephalopathies (TSE) and other animal diseases have increased the need for such materials. This paper describes the current status of a) gelatine derived from fish, b) starch and c) hydroxypropyl methylcellulose (HPMC) as potential substitutes for current gelatine two-piece capsules, including assessment of their suitability for liquid products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By William Bowtle, Technical Director at MW Encap Ltd, UK William Bowtle, Technical Director at MW Encap, is one of the leading scientists in liquid filling of hard gelatine capsules. After graduating with a first class honours degree in Pharmacy from Strathclyde University in Glasgow, Scotland, he continued his research work while assuming the post of Lecturer in Pharmaceutics, and was awarded a Pfizer Research Prize.
He later moved into industry and worked for 13 years with Eli Lilly, where, as Head of Pharmaceutical Development, he was responsible for the development of a range of oral and parenteral products for international markets. During that time he developed the 'semi-solid matrix' capsule technology. In his position as Technical Director at MW Encap, Bill is responsible for the co-ordination of all technical aspects of new products.

spacer
William Bowtle
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement